Int J Oncol 54: [Related article:] 1033-1042, 2019; DOI:
10.3892/ijo.2019.4679
Subsequently to the publication of the above article,
an interested reader drew to the authors' attention what appeared
to be a factual error associated with the reported primer sequences
for the p21 promoter. The authors have re-examined their paper
carefully, and wish to make the following textual corrections in
light of the query raised by the reader.
The first errors were located on p. 1033 and 1034, in
the Abstract and Introduction sections. First, for the sentence
beginning on line 15 of the Abstract on p. 1033, the text should be
corrected to: "UCA1 silencing in LCC2 and LCC9 cells
increased tamoxifen drug sensitivity by promoting cell apoptosis
and arresting the cell cycle at the G2/M phase," replacing "LLC2
and LLC9 cells" with "LCC2 and LCC9 cells." Secondly, in the last
paragraph of the Introduction on p. 1034, the second sentence
should be corrected to: "Induction of UCA1 overexpression in MCF-7
and T47D breast cancer cells and silencing of UCA1 in LCC2
and LCC9 breast cancer cells were performed to assess the
drug sensitivity of the cells to tamoxifen.", replacing "LLC2 and
LLC9 cells" with "LCC2 and LCC9 cells."
The next errors were located on p. 1035, in the
Materials and methods section. The primer sequences of the p21
promoter were incorrectly listed as: "Forward (40),
5′-AGACCATGTGGACCTGTCACTG-3′, and reverse,
5′-GTTTGGAGTGGTAGAAATCTGTC-3′". In fact, this primer was designed
for detecting the mRNA expression of p21, and it was inadvertently
pasted into the text during the editing process. This text should
be corrected to: "The primer sequences of the p21 promoter were as
follows: Forward (40), 5′-GAGGCAAAAGTCCTGTGTTCCAACT-3′, and
reverse, 5′-AAGAAATCCCTGTGGTTGCAGCAGCT-3′." In addition, reference
40 should have been cited as follows: Itahana Y, Zhang J, Göke J,
Vardy LA, Han R, Iwamoto K, Cukuroglu E, Robson P, Pouladi MA,
Colman A and Itahana K: Histone modifications and p53 binding poise
the p21 promoter for activation in human embryonic stem cells. Sci
Rep 6: 28112, 2016.
The final error is also located on p 1035, in the
Materials and methods section, where the supplier of anti-GAPDH
antibodies was incorrectly stated as AbMart Bio-tech Co. Ltd.,
Shanghai, China. This should be corrected to "Abcam".
Although these errors were the results of oversights
made during the writing and editing process, they do not affect the
accuracy of the study's results or the readers' comprehension of
the paper. All the authors agree with the publication of this
corrigendum, and are grateful to the Editor of International
Journal of Oncology for granting them the opportunity to
publish this; furthermore, they apologize to the readership for any
inconvenience caused.
